PuSH - Publikationsserver des Helmholtz Zentrums München

Inceptor counteracts insulin signalling in β-cells to control glycaemia.

Nature 590, 326–331 (2021)
Postprint DOI PMC
Open Access Green
Resistance to insulin and insulin-like growth factor 1 (IGF1) in pancreatic β-cells causes overt diabetes in mice; thus, therapies that sensitize β-cells to insulin may protect patients with diabetes against β-cell failure1–3. Here we identify an inhibitor of insulin receptor (INSR) and IGF1 receptor (IGF1R) signalling in mouse β-cells, which we name the insulin inhibitory receptor (inceptor; encoded by the gene Iir). Inceptor contains an extracellular cysteine-rich domain with similarities to INSR and IGF1R4, and a mannose 6-phosphate receptor domain that is also found in the IGF2 receptor (IGF2R)5. Knockout mice that lack inceptor (Iir−/−) exhibit signs of hyperinsulinaemia and hypoglycaemia, and die within a few hours of birth. Molecular and cellular analyses of embryonic and postnatal pancreases from Iir−/− mice showed an increase in the activation of INSR–IGF1R in Iir−/− pancreatic tissue, resulting in an increase in the proliferation and mass of β-cells. Similarly, inducible β-cell-specific Iir−/− knockout in adult mice and in ex vivo islets led to an increase in the activation of INSR–IGF1R and increased proliferation of β-cells, resulting in improved glucose tolerance in vivo. Mechanistically, inceptor interacts with INSR–IGF1R to facilitate clathrin-mediated endocytosis for receptor desensitization. Blocking this physical interaction using monoclonal antibodies against the extracellular domain of inceptor resulted in the retention of inceptor and INSR at the plasma membrane to sustain the activation of INSR–IGF1R in β-cells. Together, our findings show that inceptor shields insulin-producing β-cells from constitutive pathway activation, and identify inceptor as a potential molecular target for INSR–IGF1R sensitization and diabetes therapy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
49.962
8.820
11
25
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Receptor; Hyperinsulinemia; Kiaa1324
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 0028-0836
e-ISSN 1476-4687
Zeitschrift Nature
Quellenangaben Band: 590, Heft: , Seiten: 326–331 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Regeneration Research (IDR)
Helmholtz Pioneer Campus (HPC)
Institute of Diabetes and Obesity (IDO)
Institute of Experimental Genetics (IEG)
CF Pathology & Tissue Analytics (CF-PTA)
Research Unit Analytical Pathology (AAP)
Institute of Pancreatic Islet Research (IPI)
Institute of Medicinal Chemistry (IMC)
CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
30505 - New Technologies for Biomedical Discoveries
30205 - Bioengineering and Digital Health
30203 - Molecular Targets and Therapies
Forschungsfeld(er) Helmholtz Diabetes Center
Pioneer Campus
Genetics and Epidemiology
Enabling and Novel Technologies
PSP-Element(e) G-502300-001
G-501900-231
G-510002-001
G-502200-001
G-500600-004
A-630600-001
G-500390-001
G-502600-002
G-506300-001
G-502210-001
G-501900-221
Förderungen Hans-Seidl-Stiftung e.V.
German Center for Diabetes Research (DZD e.V.)
German Research Foundation
Helmholtz Portfolio Theme 'Metabolic Dysfunction and Common Disease'
Helmholtz Society
Helmholtz Future Topic 'Aging and Metabolic programming' (AMPro)
Scopus ID 85099954160
PubMed ID 33505018
Erfassungsdatum 2021-03-24